Lasa Supergenerics Limited (LASA.BO)
INR 17.88
(2.88%)
INR 17.88
(2.88%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -217.3 Million INR | 43.73% |
| 2022 | -386.2 Million INR | -624.41% |
| 2021 | -53.31 Million INR | -123.41% |
| 2020 | 227.77 Million INR | 527.76% |
| 2019 | 36.28 Million INR | 130.16% |
| 2018 | -120.3 Million INR | -197.49% |
| 2017 | 123.39 Million INR | 422.35% |
| 2016 | 23.62 Million INR | 0.0% |
| 2015 | - INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -27.31 Million INR | 82.15% |
| 2023 Q1 | -49.49 Million INR | 67.03% |
| 2023 FY | -217.3 Million INR | 43.73% |
| 2023 Q2 | -228 Thousand INR | 99.54% |
| 2023 Q3 | -14.58 Million INR | -6295.61% |
| 2023 Q4 | -153 Million INR | -949.25% |
| 2022 Q3 | -49.18 Million INR | 25.55% |
| 2022 Q1 | -120.83 Million INR | -198.37% |
| 2022 FY | -386.2 Million INR | -624.41% |
| 2022 Q4 | -150.11 Million INR | -205.2% |
| 2022 Q2 | -66.06 Million INR | 45.33% |
| 2021 Q1 | 8.06 Million INR | -78.78% |
| 2021 FY | -53.31 Million INR | -123.41% |
| 2021 Q4 | 122.84 Million INR | 360.59% |
| 2021 Q3 | -47.14 Million INR | 65.7% |
| 2021 Q2 | -137.43 Million INR | -1805.14% |
| 2020 Q2 | 70.51 Million INR | 31.23% |
| 2020 FY | 227.77 Million INR | 527.76% |
| 2020 Q4 | 37.97 Million INR | -42.07% |
| 2020 Q1 | 53.73 Million INR | 108.26% |
| 2020 Q3 | 65.55 Million INR | -7.03% |
| 2019 FY | 36.28 Million INR | 130.16% |
| 2019 Q3 | 25.76 Million INR | 670.02% |
| 2019 Q2 | -4.52 Million INR | 58.0% |
| 2019 Q1 | -10.76 Million INR | 40.21% |
| 2019 Q4 | 25.8 Million INR | 0.14% |
| 2018 Q4 | -17.99 Million INR | 65.9% |
| 2018 Q3 | -52.78 Million INR | -167.14% |
| 2018 Q2 | -19.76 Million INR | 33.6% |
| 2018 Q1 | -29.76 Million INR | 54.03% |
| 2018 FY | -120.3 Million INR | -197.49% |
| 2017 FY | 123.39 Million INR | 422.35% |
| 2017 Q2 | 86.63 Million INR | 23.15% |
| 2017 Q4 | -64.73 Million INR | -307.87% |
| 2017 Q3 | 31.14 Million INR | -64.06% |
| 2017 Q1 | 70.35 Million INR | 0.0% |
| 2016 Q1 | 53.87 Million INR | 0.0% |
| 2016 FY | 23.62 Million INR | 0.0% |
| 2015 FY | - INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 103.529% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 100.685% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 104.615% |
| Granules India Limited | 4.05 Billion INR | 105.361% |
| Indoco Remedies Limited | 984.6 Million INR | 122.07% |
| Achyut Healthcare Limited | 5.73 Million INR | 3891.103% |
| Ajanta Pharma Limited | 8.16 Billion INR | 102.663% |
| Alkem Laboratories Limited | 17.95 Billion INR | 101.21% |
| Alpa Laboratories Limited | 167.76 Million INR | 229.53% |
| Brooks Laboratories Limited | -195.91 Million INR | -10.916% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 113.455% |
| Bajaj HealthCare Limited | -837.93 Million INR | 74.066% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 128.8% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 100.39% |
| Eris Lifesciences Limited | 3.91 Billion INR | 105.544% |
| FDC Limited | 3.05 Billion INR | 107.12% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 98.553% |
| Gufic Biosciences Limited | 861.35 Million INR | 125.228% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 105.162% |
| Ipca Laboratories Limited | 5.47 Billion INR | 103.97% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 196.74% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | -10.149% |
| Laurus Labs Limited | 1.6 Billion INR | 113.535% |
| Lupin Limited | 19.14 Billion INR | 101.135% |
| Mankind Pharma Limited | 19.12 Billion INR | 101.136% |
| Medicamen Biotech Limited | 109.31 Million INR | 298.798% |
| Medico Remedies Limited | 82.9 Million INR | 362.102% |
| Megasoft Limited | -127.46 Million INR | -70.482% |
| NATCO Pharma Limited | 13.88 Billion INR | 101.565% |
| Piramal Pharma Limited | 178.2 Million INR | 221.945% |
| RPG Life Sciences Limited | 876.6 Million INR | 124.79% |
| Sigachi Industries Limited | 571.8 Million INR | 138.004% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 100.227% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 107.237% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 185.844% |
| Unichem Laboratories Limited | -704.74 Million INR | 69.165% |
| Wanbury Limited | 559.56 Million INR | 138.835% |
| Windlas Biotech Limited | 581.87 Million INR | 137.346% |
| ZIM Laboratories Limited | 172.46 Million INR | 226.001% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 100.563% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 94.388% |
| Divi's Laboratories Limited | 16 Billion INR | 101.358% |
| Hester Biosciences Limited | 188.89 Million INR | 215.044% |
| Procter & Gamble Health Limited | 2 Billion INR | 110.812% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 148.32% |
| Bal Pharma Limited | 73.92 Million INR | 393.967% |
| Strides Pharma Science Limited | -706.14 Million INR | 69.226% |
| Venus Remedies Limited | 284.9 Million INR | 176.272% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 110.019% |
| Nectar Lifesciences Limited | 49.95 Million INR | 535.047% |
| Shilpa Medicare Limited | 318.74 Million INR | 168.176% |
| Aarti Drugs Limited | 1.71 Billion INR | 112.677% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 116.165% |
| Suven Life Sciences Limited | -1.05 Billion INR | 79.319% |
| Ind-Swift Limited | 142.31 Million INR | 252.696% |
| Valiant Laboratories Limited | 3.19 Million INR | 6899.312% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 103.932% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 96.17% |
| Themis Medicare Limited | 435.23 Million INR | 149.928% |
| Hikal Limited | 696.02 Million INR | 131.221% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 101.312% |
| Sequent Scientific Limited | -358.69 Million INR | 39.417% |
| Novartis India Limited | 851.9 Million INR | 125.508% |
| Wockhardt Limited | -4.63 Billion INR | 95.307% |
| Jubilant Pharmova Limited | 771 Million INR | 128.185% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 3164.1% |
| Neuland Laboratories Limited | 3 Billion INR | 107.242% |
| Morepen Laboratories Limited | 961.59 Million INR | 122.598% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 248.825% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -139.543% |